Pessimism rises some.
For drug launch in the United States.
He also becomes SB Chairman at Slovnaft.
Czech Republic, Romania, Serbia among potential targets.
Hungary's leading pharma company reacts.
Upside potential remains high, though.
For parent company Deutsche Telekom.
OTP decline in May has a lot to do with popularity.
For its incentive programme.
That is more than EUR 3.8 million.
Recommendations for Esmya approved by CHMP.
Fonte Viva was established in 2002.
To HUF 5,470 from HUF 5,695.
It is focused on Brexit impacts at the moment.
Shareholders must be happier than life insurance policy holders.
On 22 June, 2018.
Esmya may remain on markets but with restrictions.
Beats expectations by miles.
For HUF 70 million, for incentive programme.